Accounting for 14,000 deaths in the USA last year, research informs us that advanced
bladder cancer is a lethal disease with a median survival that has remained a little over 1 …

Background: Vinflunine is a novel second generation of Vinca alkaloid. The binding of
vinflunine to tubulin and subsequent cellular arrest in mitosis is the core mechanism of this …

Vinflunine is a second-generation Vinca alkaloid distinguished from other related
compounds by differences in tubulin binding affinities and its effects upon microtubule …

Background: A systematic review and meta-analysis of the use of systemic vinflunine (VIN)
in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on …

BACKGROUND: The activity and safety of vinflunine was evaluated in patients with locally
advanced or metastatic urothelial carcinoma (UC) who developed disease progression …

In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of
platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study …

The aim of this study was to evaluate the effectiveness and toxicity profile of the vinflunine
chemotherapy regimen and to examine the cost-effectiveness relation in a real-world …

Background: Vinflunine is the only cytotoxic agent that had been tested as a second line
therapy in platinum refractory urothelial carcinoma patients in a phase III clinical trial. The …

Background: Based on the results of phase III trial, vinflunine was approved by European
Medicines Agency in 2010 as second line treatment of advanced urothelial cancer in …

Background Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic
urothelial cancer after failure of platinum-containing therapy. We performed a systematic …